Study of Hydronidone and How It Leaves the Body
Part of Digestive system clinical trials.
This study tests how a drug called hydronidone is processed and removed from the body using a very small amount of radioactive labeling. It helps researchers understand how the drug works, so it may lead to better treatments for conditions like liver fibrosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a Chinese male aged 18 to 50 years old
- Weigh at least 50 kg (110 lbs) and have a BMI between 19 and 26
- Agree to use effective birth control and not donate sperm for 6 months after the study
- Have no major medical conditions like heart, liver, or mental health issues
- Not have taken any prescription or over-the-counter drugs or supplements in the last 14 days
- Have a negative test for hepatitis B, C, syphilis, and HIV
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether hydronidone capsules can help people with long-term hepatitis B–related liver scarring (fibrosis). It aims to track whether treatment reduces or delays serious liver complications over time.
This trial tests a new injection called AHB-137 for people with chronic hepatitis B. It aims to see if the drug is safe and helps control the virus.
This trial tests a long-term treatment called hydronidone for liver scarring (fibrosis) caused by chronic hepatitis B. It aims to see if the treatment can help slow or reverse liver damage in people who are already on antiviral therapy or starting treatment for the first time.
This trial tests a new medicine called Hydronidone Capsule in healthy people to see how the body processes it and whether it is safe. If you are in good health, you may be able to join this first-in-human study.
This study tests how a new investigational drug called AHB-137 moves through your body and affects safety in people with mild-to-moderate liver problems compared to people with normal liver function. The goal is to understand if the drug works safely in people whose livers don't work as well as they should.
This study tracks how a new experimental drug (HRS-1780) moves through and leaves your body. Researchers will give you a single dose and measure where it goes and how it's eliminated, which helps them understand if it's safe for future patients.
Hear when a new Chronic Hepatitis B-related Liver Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.